


# Global Psoriasis Biosimilars Market Poised for Significant Growth, Expected to Reach USD 26,679.9 Million by 2034

*Germany's psoriasis biosimilars market, growing at a 7.7% CAGR (2024-2034), leads in Western Europe. Strong R&D, strict regulations, and expert healthcare.*

NEWARK, DE, UNITED STATES, January 7, 2025 /EINPresswire.com/ -- The [global psoriasis biosimilars market](https://www.einpresswire.com/news/global-psoriasis-biosimilars-market) is on a trajectory of robust growth, with its market value expected to surge from USD 9,228.6 million in 2024 to an impressive USD 26,679.9 million by 2034, according to recent market projections. This growth represents a remarkable compound annual growth rate (CAGR) of 11.2% over the forecast period, signaling the increasing adoption of cost-effective, high-quality biosimilar therapies for the treatment of psoriasis.



Psoriasis Biosimilars Market

In 2023, the market generated USD 8,412.6 million in revenue, reflecting its accelerating momentum and the growing acceptance of biosimilars among healthcare providers and patients worldwide.


**Key Growth Drivers: Rising Psoriasis Cases and Need for Affordable Treatment**

The rising prevalence of psoriasis, a chronic inflammatory skin condition, is the primary factor propelling market growth. As millions globally battle the physical and psychological challenges of this condition, the demand for effective, accessible, and affordable treatment options has surged. Biosimilars, which are near-identical versions of original biologics, offer a cost-effective alternative without compromising efficacy or safety standards, addressing this growing need.

Gain Valuable Market Knowledge:  
Request a Sample Report!  
<https://www.futuremarketinsights.com/reports/sample/rep-gb-19805>

## Biosimilars: Enhancing Accessibility to Biotherapy

Biosimilars play a critical role in enhancing patient access to advanced biotherapies. Unlike traditional biologics, which often come with high price tags, biosimilars provide a more affordable option. This is particularly vital in regions like the United States, where psoriasis imposes significant economic burdens. By offering comparable efficacy at reduced costs, biosimilars help bridge the gap for underutilized biotherapy treatments, ensuring more patients can benefit from innovative care solutions.



Regional Analysis of Psoriasis Biosimilars Market

## Regional Impacts: Addressing Economic and Medical Needs

In America, where the prevalence of psoriasis is growing, the economic implications are considerable. The introduction of biosimilars can alleviate financial strain on healthcare systems while improving outcomes for patients. With affordability and accessibility as key advantages, biosimilars are positioned to reshape the treatment landscape for psoriasis globally.

## Future Outlook:

The psoriasis biosimilars market is on track to witness transformative growth over the next decade, driven by increasing awareness, affordability, and patient accessibility. As pharmaceutical advancements continue to expand the reach of biosimilar therapies, the global healthcare community stands to benefit from enhanced treatment options for psoriasis sufferers worldwide.

## Key Takeaways:

- The market size in 2023 was valued at USD 8,412.6 million.
- The estimated market size for 2024 is USD 9,228.6 million.
- By 2034, the market is projected to reach USD 26,679.9 million, reflecting significant growth.

- The compound annual growth rate (CAGR) from 2024 to 2034 is forecasted to be 11.2%.
- The USA is expected to see a value-based CAGR of 7.9% from 2024 to 2034.
- Canada is projected to experience a robust CAGR of 10.8% over the same period.
- The UK's market growth is forecasted at a value-based CAGR of 8.2%.
- Germany is expected to grow at a value-based CAGR of 7.7%.
- France is projected to see a 9.1% value CAGR.
- Italy is anticipated to grow at a value-based CAGR of 9.7%.
- India is expected to witness the highest growth, with a projected CAGR of 11.3%.
- Spain is forecasted to see a value-based CAGR of 10.4%.

Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!

<https://www.futuremarketinsights.com/reports/psoriasis-biosimilars-market>

### Competitive Landscape:

Companies in the psoriasis biosimilars market are enhancing their distribution networks and integrating supply chains to expand their market reach. They are focusing on emerging markets with growing healthcare needs and an increasing patient population, while maintaining cost-effective manufacturing processes.

This approach is crucial for improving the accessibility of biosimilars to a wider patient base. Additionally, companies are navigating complex regulatory pathways to gain approval for their biosimilars. They collaborate closely with regulatory authorities to address safety, efficacy, and quality concerns, adhering to rigorous standards.

### Recent Industry Developments in the Psoriasis Biosimilars Market:

- July 2024: Cooper Consumer Health successfully acquired the over-the-counter (OTC) business of Viatris Inc.
- May 2024: Novartis Pharmaceuticals Canada Inc. announced a partnership with Clarius Mobile Health to enhance early detection of psoriatic arthritis in Canada.

### Key Players of Psoriasis Biosimilars Market:

- Merck KGaA
- Gyros Protein Technologies AB
- Pfizer Inc.
- Novartis International AG
- Amgen Inc
- Samsung Bioepis Co., Ltd.
- Coherus BioSciences
- Hoffmann-La Roche Ltd
- Celltrion

- Samsung Bioepis
- Sandoz
- Fresenius Kabi
- Viatris
- Reddy's Laboratories
- GenScript

#### Key Segments of Psoriasis Biosimilars Market:

##### By Drug Class:

In terms of drug class, the industry is divided into TNF-alpha inhibitors (infliximab, etanercept, adalimumab) and other biosimilars.

##### By Indication:

In terms of Indication, the industry is segregated into plaque psoriasis, psoriatic arthritis and other types.

##### By Route of Administration:

In terms of route of administration, the industry is segregated into subcutaneous, intravenous oral and topical.

##### By Distribution Channel:

In the terms of distribution channel, the market is segmented into hospital pharmacies, retail pharmacy chains and online pharmacies.

##### By Region:

Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia and Middle East and Africa (MEA) have been covered in the report.

#### Explore FMI's Related Ongoing Coverage on Healthcare Market Insights Domain:

The [global psoriatic arthritis \(PsA\) treatment market size](#) is set to acquire a value of USD 11,973.7 million in 2024. By 2034, the value of the psoriatic arthritis (PsA) treatment market is slated to shoot upwards of USD 25,375.6 million. As such, the sector is anticipated to progress at a CAGR of 7.8%.

The [global autoimmune disease therapeutics market demand](#) is likely to be valued at USD 71,466.47 million in 2023 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of USD 123,507.30 million by 2033.

#### About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of

the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.  
Christiana Corporate, 200 Continental Drive,  
Suite 401, Newark, Delaware - 19713, USA  
T: +1-347-918-3531  
For Sales Enquiries: [sales@futuremarketinsights.com](mailto:sales@futuremarketinsights.com)  
Website: <https://www.futuremarketinsights.com>

Ankush Nikam  
Future Market Insights, Inc.  
+91 90966 84197

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/774720393>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.